Owing to the heterogeneity of AML, the indication for allogeneic SCT (allo-SCT) requires an exact definition of the individual subentity and risk category. A comprehensive diagnostic approach is needed, which combines cytomorphology, cytogenetics, FISH, molecular genetics and immunophenotyping. Whereas the categorization in three prognostic karyotype groups is well established, rare recurrent aberrations as the unfavorable t(8;16)(p11;p13), inv(3)(q21q26) and t(6;9)(p23;q34) must also be considered. In normal karyotype, PCR analyses reveal prognostically relevant mutations in 485% of cases, and a molecular data set composed of the FLT3-ITD, MLL-PTD, NPM1 and CEBPA mutations was found able to guide the selection of patients for allo-SCT. Some novel markers as the WT1 mutations might further contribute to risk stratification in normal karyotype. The panel of minimal residual disease parameters is being expanded at this time, for example, by quantitative PCR for the NPM1 mutations. Immunophenotyping allows the definition of leukemia-associated phenotypes in nearly all cases, but its position in the indication to allo-SCT has to be validated. Thus, the optimization of the indication to allo-SCT is an ongoing process that should remain in continuous interaction with the increasing panel of known genetic markers and diagnostic methods.
Introduction
Owing to the heterogeneous profile from clinical, morphological, immunological and genetic aspects, AML is understood as a complex of diverse biologically and prognostically relevant subtypes. A combination of cytomorphology, immunophenotyping, and cytogenetics and molecular genetics only provides the essential parameters for a correct classification of the individual subtype. 1 In recent years, especially the diverse FISH and PCR techniques gained importance. The panel of known genetic markers is still increasing, 2 and the impact of minimal residual disease (MRD) detection was realized for several AML subtypes. [3] [4] [5] [6] Modern therapy concepts aim to restrict the risks of transplant-related morbidity and mortality and of reduced quality of life post transplant 7 for those patients with unfavorable outcomes after standard treatment. Thus, the indication to allogeneic SCT (allo-SCT) must now integrate the complete pattern of diagnostic results at diagnosis and during follow-up of AML. Considering the variety of diagnostic parameters and methods that are available for the variety of subtypes, this became a real challenge.
On the basis of the detection of aberrant karyotypes in B55% of AML cases, the categorization in good, intermediate and inferior risk groups has been established in diverse large studies. [8] [9] [10] However, less frequent cytogenetic aberrations and the combination of diverse genetic markers-for example, a t(8;21)(q22;q22) combined with a ÀY in males, 11 or with a cKIT mutation; 12, 13 or the t(15;17)/PML-RARA with an FLT3-ITD (internal tandem duplication of the FLT3 gene) or FLT3-TKD (tyrosine kinase domain) mutation 14 -can complicate decisions. The detection of recurrent molecular markers in the majority of patients with a normal karyotype 15 completely changed understanding of the so-called 'intermediate prognostic group'. Likewise to the prognostically adverse FLT3-ITD that were identified as adverse prognostic markers in AML less than a decade ago, 16, 17 by now the favorable Nucleophosmin (NPM1) mutations in 55% of normal karyotype AML 2, 18 have an increasing influence in therapeutic decisions. For some other mutations, for example, FLT3-TKD 16, 19, 20 or NRAS, 21, 22 the impact on prognosis is still controversial. Mutations of the Wilms' tumor suppressor gene (WT1) 23, 24 and overexpression of the WT1 25, 26 or BAALC (brain and acute leukemia, cytoplasmic) genes 27 were identified as adverse prognostic parameters, but whether they might have a role in the indication to allo-SCT in normal karyotype cases needs additional investigation.
An early evaluation of the response to induction therapy can be performed by a combination of BM cytomorphology, 28 multiparameter flow cytometry 29 and quantitative PCR (qPCR). 5 The measurement of the residual cell load by multiparameter flow cytometry and qPCR allows a more sensitive estimation of persistent disease than cytomorphology and an earlier detection of relapse before the morphological manifestation. 3, 4 Although previously molecular MRD diagnostics were available for some reciprocal rearrangements as the t(8;21)/RUNX1-RUNX1T1 only, qPCR is currently being established for a larger spectrum of molecular markers as the NPM1 mutations, [30] [31] [32] the FLT3 mutations [33] [34] [35] and the MLL-PTD, 36 aiming to provide MRD measurement also in normal karyotype cases.
This work gives an overview on the increasing panel of genetic markers, diagnostic techniques and follow-up investigations that became essential for the indication to allo-SCT in AML. In addition, attention is paid to novel markers that might contribute to this complex decision in the future.
Cytomorphology
Cytomorphology still represents one of the basic methods for the indication to allo-SCT in AML. Currently, response to induction therapy is assessed with a day þ 28 BM aspirate and/or biopsy. However, recent data indicated that early response to induction chemotherapy with a reduction in the day 14 or 16 marrow blasts ('day 16 blasts') to o5-10% is associated with a higher likelihood of achieving a CR. 28, 37, 38 Indeed, as being demonstrated in a large study of 680 AML patients, CR rates of patients with intermediate karyotype but day 16 blasts o10% were comparable to the cohort with favorable cytogenetics. 39 Wells et al. 40 demonstrated in 498 pediatric patients that a threshold of X15% BM blasts on day þ 14 after the start of induction therapy was associated with lower remission rates. Thus, persistence of higher blast percentages once induction is completed should always raise concern whether there might be an indication for allo-SCT. 37 
Immunophenotyping
Multiparameter flow cytometry is able to detect specific leukemia-associated immunophenotypes (LAIP) in 95% of AML patients at diagnosis. [41] [42] [43] These are based on aberrant coexpression of lymphatic Ags (for example, of CD7), asynchronous coexpression of Ags of different maturation stages, aberrant low or bright Ag expression, or Ag loss, for example, loss of HLA-DR in myeloid blasts. Sensitivities of 10 À2 to 10 À4 are achieved. 44 The comparison of the proportions of cells with the respective LAIPs before and after therapy for an early and sensitive evaluation of the response to treatment 41, 45 can also be performed when molecular markers for follow-up investigations are not available. Also, the logarithmic difference between LAIPpositive cells on days þ 1 and þ 16 after the start of therapy was shown to correlate significantly with the achievement of CR, overall survival (OS) and disease-free survival (DFS). 41, 46 Coustan-Smith et al. 47 demonstrated that the reduction of aberrant cells to a threshold of 0.1% is a predictor of long-time survival. Another study demonstrated that the reduction of cells carrying the leukemia-specific immunophenotype after induction or consolidation therapy when compared to diagnosis was significantly associated to relapse-free survival. The prognostic impact of flow cytometry was independent of cytogenetics or other prognostically relevant parameters in multivariate analysis. 48 In addition, numerous studies demonstrated an increase of LAIP-positive cells before the occurrence of morphological relapse. In a study on 252 pediatric patients with AML, a proportion of 40.5% cells with the aberrant blast phenotype was associated with a threefold increased relapse risk when compared to patients below this threshold. 49 Laane et al. 6 performed multiparameter flow cytometry analyses in 45 AML patients p60 years of age first at the time of cytomorphological CR and at a second time point after induction/post-remission chemotherapy or before SCT: patients with detectable MRD who did not proceed to allo-SCT had a 5-year DFS of 20-25% only, whereas those receiving an allograft had a similar outcome as MRD-negative patients and did fairly better. Venditti et al. 50 determined a threshold of 3.5 Â 10 À4 aberrant cells being predictive for relapse.
Although these results suggest that an increase of LAIPpositive cells after therapy might be interpreted as possible indication for allo-SCT, 6 the final position of multiparameter flow cytometry in the indication to allo-SCT in AML has to be further established.
Cytogenetics
Chromosome banding analyses are obligatory at diagnosis or relapse of AML. Considering the limited sensitivity of chromosome banding and the requirement of 20-25 metaphases for valid results, the combination with diverse molecular FISH techniques thereby became highly important. This can be illustrated by complex karyotypes, which were never fully understood before the introduction of multicolor FISH.
On the basis of cytogenetics, cases are separated into three prognostically relevant groups. In the 'favorable group' with the recurrent reciprocal translocations t(15;17)/ PML-RARA, t(8;21)/RUNX1-RUNX1T1 and inv(16)/ CBFB-MYH11, allo-SCT was removed from the first-line strategies in first CR but still remains an option in case of relapse. [51] [52] [53] The coincidence of an FLT3-ITD and a PML-RARA might confer an inferior prognostic impact, 14 but this observation is so far based on few studies only. Also, it was suggested that the t(8;21) and the inv(16) core binding factor leukemias have an inferior prognosis when being combined with a loss of Y in males. 11 In contrast, the combination of an inv(16)/CBFB-MYH11 with an additional trisomy 22 is prognostically even more favorable when compared an isolated inv(16), 11, 15 which demonstrates the relevance of additional aberrations in the CBF leukemias.
The second 'intermediate subgroup' mainly includes normal karyotype and an isolated trisomy 8. However, also all cytogenetic abnormalities with so far unknown impact on prognosis due to their low incidence are included Diagnostics in the indication to allo-transplantation in AML U Bacher et al in this category. Whereas trisomy 8 is prognostically not relevant when being found as sole aberration, an unfavorable influence was suggested when the þ 8 is found in combination with other (noncomplex) abnormalities. 10, 54, 55 In contrast, a recent study investigating 131 AML patients with a noncomplex þ 8 showed no prognostic difference when additional cytogenetic abnormalities were present (excluding the favorable reciprocal rearrangements). Only presence of 480% positive metaphases carrying the þ 8 was associated with inferior survival. 56 With respect to normal karyotype, the optimal postremission treatment strategy was until recently controversial, 57 but current transplantation strategies rather base the indication to allo-SCT on the results of molecular screening (Table 1) . 58 The third 'unfavorable group' includes unbalanced karyotypes with numerical or structural gains or losses of chromosomal material ( Table 2 ). Deletions of 5q or 7q and losses of chromosome 7 have major functions. In twothirds of cases, mutations or deletions of the P53 tumor suppressor gene on 17p13 are observed. Prognosis is dismal also in MLL/11q23 rearrangements (mixed lineage leukemia gene), which are often seen in association with previous application of topoisomerase II inhibitors. In these unfavorable cytogenetic subtypes, relapse rates after standard chemotherapy are up to 80%. Improved outcome was suggested in the subgroup with a t(9;11)(p22;q23)/ MLL-AF9 when compared to other MLL/11q23 rearrangements. 54, 65 This, however, was not confirmed in another study of 54 patients with MLL/11q23 rearrangements. 66 Also in childhood AML the prognostic impact of the t(9;11) remains controversial. 67, 68 In the new WHO classification the t(9;11)(p22;q23)/MLL-AF9 defines an own AML subtype. 69 Especially in complex aberrant karyotypes with the simultaneous occurrence of X3 clonal chromosomal anomalies (being identified in 10-15% of all AML cases), stable remissions are extremely rare after standard chemotherapy. 70 Complex aberrant karyotypes are not randomly distributed but frequently involve losses in the 5q14q33, 7q32q35 and 17p13 regions (the latter containing the P53 tumor suppressor gene). 71 Recently, Breems et al. 72 suggested that a 'monosomal karyotype' as defined by the combination of X2 numerical autosomal losses or the combination of an autosomal loss and a structural alteration was a better predictor of an unfavorable prognosis than the traditional definition of complex aberrant karyotypes. However, this aspect needs additional investigation as these data result so far from one study only. So far, allo-SCT seems the only possibility to achieve stable remissions in the prognostically unfavorable group. In a large EORTC/GIMEMA study in adult AML patients p45 years of age, allo-SCT in first remission improved DFS from o20% to 440% when compared to intensive or high-dose chemotherapy. 73 In patients with chromosome 5 or 7 alterations, a 3-year OS of only 25% was reported even when allo-SCT was performed, mainly due to a 480% relapse rate in patients 440 years of age, whereas those p40 years had a better outcome. 74 Cytogenetics are predictive for the outcome of therapy also in therapy-associated AML (t-AML). Within the WHO classification, this entity now belongs to the category of therapy-related myeloid neoplasms, which also includes therapy-associated MDS and MDS/MPN (representing cases with overlapping myelodysplastic and myeloproliferative characteristics). 69 Armand et al. 75 found equal survival in the diverse cytogenetic subgroups independently of a de novo manifestation or an association with previous therapy in 556 patients with MDS or AML undergoing allo-SCT. Nevertheless, karyotypes are differently distributed in de novo and t-AML. First, aberrant karyotypes are more frequent in therapy-associated cases with aberration rates as high as 80% in comparison to 55% in de novo cases. Second, unfavorable karyotypes are found in t-AML with a 445% frequency but in 20% of cases in de novo AML only. 76 Likewise, in secondary AML after MDS (s-AML) (or AML with myelodysplasia-related changes according to the new WHO classification) 69 prognostically adverse karyotypes are overrepresented. 77, 78 Owing to this unfavorable prognostic profile, s-AML is frequently considered to represent an indication to allo-SCT. A retrospective European Group for Blood and Marrow Transplantation study demonstrated a 3-year OS of 31% in patients with advanced MDS or s-AML, however with a high transplantrelated mortality (TRM) of 52% 79 before the introduction of dose-reduced strategies.
Also at relapse of AML, cytogenetics are highly relevant for the evaluation of prognosis. As the favorable impact of the reciprocal rearrangements from the first WHO hierarchy can also be determined, the karyotype was included in prognostic scores for patients at relapse of AML. 80 Rare recurrent cytogenetic aberrations 3q21q26 aberrations The inv(3)/t(3;3)(q21;q26) is detected in 0.5-1% of all AML patients, but interphase FISH or PCR reveal slightly Diagnostics in the indication to allo-transplantation in AML U Bacher et al higher frequencies of cryptic 3q26 breakpoints up to 2%. 81 Fusion of EVI1 or the related MDS/EVI1 genes at 3q26 and RPN1 results in increased EVI1 expression, which is significantly associated with worsened OS. 81 Allo-SCT was reported to result in a 2-year OS of 62% in 12 inv(3) patients, whereas standard therapy is followed by relapse rates as high as 50%. 82 Translocation t(6;9)(q23;q34) The unfavorable t(6;9)(q23;q34)/DEK-NUP214 rearrangement is found in 0.5-1% of adult AML patients. 83 In some of the cases, coincidence with FLT3-ITD might contribute to the adverse prognosis. 84 Prognosis seems to be ameliorated by allo-SCT, at least when complete molecular remission is achieved before transplantation: Garcon et al. 85 reported DFS of 13-95 months in four patients having achieved molecular CR before allo-SCT, whereas those seven patients remaining MRD positive all developed relapse after SCT.
Translocation t(8;16)(p11;p13) The rare reciprocal t(8;16)(p11;p13) is characterized by fusion of the MYST3 and CREBBP genes. This results in an aberrant protein-MYST3-CREBBP-which is considered to inhibit RUNX1/AML1-mediated transcription. 86 The blasts are characterized by the phenomenon of erythrophagocytosis 87 and by the unique combination of positive myeloperoxidase and nonspecific esterase staining in 480% of cells. Similar to the MLL/11q23 rearrangements, there is a close association with previous application of topoisomerase II inhibitors 88 with exposure to radiation. 89 Further, AML with MYST3 rearrangements was shown to be characterized by an outstanding gene expression profile, which shows parallels to T-cell ALL; thus, targeting of a common T-myeloid progenitor was suggested. 90 So far, survival of a few months only was reported in most cases of MYST-rearranged AML, 87 and none of four patients reported by Quesnel et al. 91 achieved CR after standard chemotherapy. Gervais et al. 92 reported a mortality rate of 50% in the so far largest study of 30 cases with MYST3/8p11 rearrangements. Successful allo-SCT was reported in one case by Demuynck et al. 93 Although the rare occurrence of the translocation has to be seen, there seems to be a clear indication to allo-SCT in the t(8;16).
Rare numerical trisomies
Numerical gains other than þ 8 in noncomplex karyotypes are rare in AML and are mainly represented by gains of the chromosomes 11, 13 and 21. They are all associated with a dismal prognosis. In trisomy 11 cases, the frequent coincidence of the prognostically adverse MLL-PTD might contribute to the inferior prognosis. 94 In case of trisomy 13, the frequent association with RUNX1/AML1 mutations combined with increased FLT3 gene expression could be relevant for the inferior outcome. 95, 96 According to Farag et al. 55 who analyzed 101 patients with isolated trisomies, survival was 5% only in standard treated patients in comparison to close to 70% in patients receiving allo-SCT. 
Molecular criteria

NPM1 mutations
Mutations of the NPM1 gene are detected in B30% of all AML patients and in 55% of normal karyotype patients. When detected as isolated mutations in normal karyotype, they confer a favorable prognosis. Mostly 4 bp insertions alter the structure of the NPM1 protein, which in consequence is aberrantly localized to the cytoplasm. This is supposed to interfere with the normal participation of the protein within the ARF53 tumor suppressor pathway. 18 With respect to the distinct clinical and biological profile, the WHO classification recently categorized NPM1-mutated cases separately as provisional entity. 69 Recently, Schlenk et al. 58 demonstrated in a retrospective analysis of 872 patients with normal karyotype aged o60 years that in case of isolated NPM1 mutations without an FLT3 mutation, allo-SCT was not able to confer a benefit in first remission, whereas outcome was improved by allo-SCT in case of a concurrent FLT3 mutation or MLL-PTD. The deterioration of prognosis in NPM1-mutated cases by an additional FLT3-ITD has been described before in several larger studies. [97] [98] [99] [100] In elderly patients, the favorable impact of NPM1 mutations might be weaker. Scholl et al. investigated 99 elderly patients between 60 and 85 years and found an improved remission rate but no significant survival difference when patients with and without isolated NPM1 mutations were compared. 82, 101 Thus, it might be speculated whether elderly patients with isolated NPM1 mutations might still benefit from allo-SCT with dosereduced conditioning. 101 CEBPA mutations In 9% of AML patients, mutations of the CEBPA gene coding for the respective transcription factor are identified. They are specifically associated to normal karyotype. The CEBPA gene that encodes the CAAT/enhancer-bindingprotein-a 0 transcription factor is essential for regulation and differentiation of granulopoiesis. CEBPA mutations inhibit the normal function of the CEBPA transcription factor. 102 As isolated alterations in AML with normal karyotype, CEBPA mutations predict a favorable prognosis. 62, 103 The CEBPA mutations also achieved the status of a provisional entity within the revised WHO classification. 69 First-line allo-SCT had no beneficial effect in patients with an isolated CEBPA mutation in the above study of Schlenk et al. 58 when compared to standard treatment.
FLT3 mutations
The most frequent mutations of the FLT3 gene, which codes for the respective receptor class III kinase, 104 are represented by internal tandem duplications (FLT3-ITD) in B40% of all patients with a normal karyotype. 33, 61 They are localized in the domain that codes for the juxtamembrane domain of the FLT3 receptor. 105 Mutations of the TKD are less frequent in B8% of all AML cases. Whereas FLT3-ITD were concordantly shown to contribute a significant unfavorable prognostic impact, 16, 17, 61 the influence of the TKD mutations is controversial 106 but seems to be weaker and to depend on cooperating mutations. 19 In FLT3-ITD, standard chemotherapy is followed by high relapse rates of 480%. 51 In previous studies, allo-SCT improved survival from 20-25 to 45-50%. 107 Schlenk et al. 58 demonstrated the beneficial effects of allo-SCT in first remission for FLT3-ITD and FLT3-TKD. In a study of the Czech Acute Leukemia Clinical Register, median OS of patients with an FLT3-ITD was 42 weeks in comparison to 29 weeks for those receiving standard chemotherapy, and allo-SCT was able to abolish the differences in outcome of FLT3-positive and wild-type patients. 108 However, most recommendations on the application of allo-SCT vs conventional therapy in FLT3-mutated AML derive from retrospective studies. Finally, in a large study of 1135 patients performed by Gale et al., 109 the adverse outcome of patients with an FLT3-ITD was not influenced by allo-SCT. Thus, at this time the benefit of an allo-SCT in patients with AML and FLT3-ITD remains unclear. 110 
MLL-PTD
Partial tandem duplications of the MLL gene (MLL-PTD) are intragenic MLL abnormalities with a specific association to normal karyotype AML (5-10%). They are interpreted as gain-of-function mutations. 94 Likewise to interchromosomal MLL alterations they are prognostically unfavorable. 63, 66, 111 Also in this subgroup, Schlenk et al.
58
found a prognostic benefit in case of an early allo-SCT. In 430% of all MLL-PTD cases, FLT3-ITD are found in coincidence with the MLL-PTD. 112, 113 Whether such co-duplication is of clinical relevance when compared to a single mutation has to be determined by additional cases.
Parameters that might become relevant in the future
Mutations of the KIT-tyrosine kinase (another class III receptor tyrosine kinase) are mostly localized in exon 17 of the activation loop. 12 They are rare in total AML, but show a 440% frequency in the t(8;21)/RUNX1-RUNX1T1 and inv(16)/CBFB-MYH11 core binding factor leukemias. 114, 115 At least in the t(8;21) they confer a unfavorable clinical impact. 12 Considering the small population of patients carrying a KIT mutation and a t(8;21)/RUNX1-RUNX1T1 in coincidence, randomized trials will be difficult to perform. Thus, at this time, a final recommendation whether the coincidence of a KIT mutation and the t(8;21)/RUNX1-RUNX1T1 should be considered in the indication to allo-SCT is not possible. Treatment conclusions ultimately have to be based on retrospective analysis of the outcome of chemotherapy vs early intensification/ consolidation with an allo-SCT.
For some mutations that are found associated with normal karyotype AML, the prognostic impact still has to be defined, for example, for mutations of the RUNX1 (AML1) gene that encodes the respective transcription factor. 84 Mutations of the RAS-oncogenes function by constitutive activation of the RAS pathway. 116 NRAS mutations are detected in 10% of all AML cases, but seem to influence prognosis in some cytogenetic and molecular subgroups only. 21, 22 Mutations of WT1 were detected in 10% of all AML patients with a specific association to normal karyotype. They seem to be associated with failure to achieve CR, 117, 118 and an unfavorable prognosis. 23 Their inclusion in a risk-adapted stratification of patients with normal karyotype AML is in discussion. 24 Also, overexpression of the respective WT1 gene might become relevant in the future, as this gene is highly expressed in various hematological malignancies and also in AML. 119 The same applies to the BAALC gene that is primarily expressed in neuroectoderm-derived tissues and in hematopoietic precursors. High expression correlates in normal karyotype AML with a negative prognosis. 64, 120 Also, overexpression of the ERG (ETS-related), 121 MN1 (meningioma-related) 122 and EVI (ecotropic virus integration-1) 81 genes seemed to be associated to a negative prognostic impact in few studies, but data are limited at this time.
Minimal residual disease diagnostics
In the reciprocal gene fusions t(15;17)/PML-RARA, t(8;21)/RUNX1-RUNX1T1 and inv(16)/CBFB-MYH11, [3] [4] [5] quantitative real-time PCR achieves sensitivities of 10 À5 to 10 À6 123 and thus is suitable for quantification of the residual leukemic cell load at an early time point after therapy. 5 The score of the aberrant gene expression compared after consolidation therapy and at diagnosis was shown to be significantly associated with survival. 124 Persistence 52 or minor decrease of transcript copy numbers 5 predicts an enhanced relapse risk. A threshold of p1% of the initial mutated cell load was determined to correlate with an increased relapse risk in patients with core binding factor leukemias 125 and in another study a transcript number of 410 during follow-up was found to correlate with significantly shortened OS in inv(16) cases. 126 An increase of the respective fusion transcripts precedes the morphological manifestation of relapse by an interval of 3-6 months and therefore represents a possible indication to allo-SCT.
To reach more AML subgroups and especially patients with a normal karyotype, MRD strategies are being developed for novel markers, for example, the NPM1 mutations. Recent studies performing quantitative realtime PCR demonstrated that the NPM1 mutations represent stable follow-up parameters. 30, 31, 127, 128 For patients with an FLT3-ITD, the course of disease can be monitored by semiquantitative PCR, 33 whereas exact quantitative measurement requires the labor-intensive design of patient-specific primers due to the heterogeneous mutation profile. 34 However, the high instability rates up to 17% in relapsed patients raise doubts on the validity for MRD purposes. 129 Others, in contrast, suggested that loss of the mutation occurs in o5% of cases only and that accumulation of the mutation with a higher ratio of mutated to unmutated alleles is associated with an increased relapse risk. 33 For FLT3, TKD assays for quantitative monitoring are being developed as well. 35 Also in the MLL-PTD, a threshold of a 2log reduction of expression when compared before and after treatment was found to be significantly associated with prognosis. 36 Another parameter that might gain importance for follow-up strategies is WT1 expression. 119, 123 Overexpres- Diagnostics in the indication to allo-transplantation in AML U Bacher et al sion is seen in various leukemia types and especially in AML. 119, [130] [131] [132] However, the definite position of WT1 expression for the planning of allo-SCT is not yet determined, and the physiological expression of WT at lower levels in healthy individuals might disturb the interpretation of MRD results. A recent comparison of NPM1 mutations and WT1 expression demonstrated superiority of the NPM1 mutations when quantitative real-time PCR was performed for both parameters. 127 
Discussion
Meanwhile, the combination of chromosomal and molecular markers allows a categorization of nearly all AML cases in subgroups with distinct clinical profiles 69 as a basis for an individualized risk-based indication to allo-SCT (Figure 1) . 51 Only a comprehensive diagnostic approach combining morphology, immunophenotyping, and diverse cytogenetic and molecular genetic techniques is able to provide the basis for this differentiated risk stratification. One recent major contribution was the definition of a molecular data set composed by the NPM1, FLT3-ITD and -TKD, MLL-PTD and CEBPA mutations, which is able to predict whether patients with a normal karyotype might benefit from an early allo-SCT. 58 Trying to define a hierarchy of mutation screening in normal karyotype AML cases, analysis for the NPM1 and the FLT3-ITD mutations should be obligatory, preferentially being combined with analysis for the CEBPA mutations and MLL-PTD. Whether novel molecular markers as the WT1 mutations might contribute to this indication in the future, still has to be defined. 117, 118 Also, the panel for the measurement of MRD is continuously expanding. Especially the NPM1 mutations seem to provide very stable and sensitive parameters. 30, 31, 127 The combination of immunophenotyping and molecular genetics for MRD detection might be a further step to more safety in the post-treatment period. Measurement of gene expression, for example, of WT1 119, 123 or BAALC, 64, 120 represents another promising approach for MRD measurement in myeloid malignancies.
Novel methods, such as gene expression profiling by microarrays that allows the simultaneous measurement of the expression of tens of thousands of genes, might contribute to a more detailed risk stratification for allo-SCT. 133 One approach is the definition of diverse prognostic groups within defined genetic subtypes on the basis of distinct gene expression patterns as being shown in normal karyotype AML 134, 135 or in core binding factor leukemias. 136 Assays to predict the sensitivity to distinct antileukemic compounds as demonstrated by Raponi et al. 137 for the farnesyltransferase inhibitor tipifarnib might be helpful to perform selection of patients who probably will have no benefit from pharmacological approaches. Likewise to the progress in molecular risk stratification in normal karyotype, 58 these examples indicate that the indication to allo-SCT should remain in continuous interaction with the expansion of diagnostic methods and prognostically relevant markers 18 to further optimize this complex decision in the heterogeneous disorder of AML.
